8-K: Kairos Pharma Reports Positive Safety Results for ENV-105 in Advanced Prostate Cancer Phase 2 Trial

Kairos Pharma, Ltd. announced positive interim safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) for metastatic castration-resistant prostate cancer, showing the drug was well tolerated with no Grade 3 or 4 toxicities.

Summary

• Kairos Pharma announced positive interim safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC).
• The interim safety analysis, based on the first ten enrolled patients, demonstrated that ENV-105 was well tolerated when combined with standard of care hormone therapy, apalutamide.
• No dose-limiting toxicities or unexpected adverse events have been reported to date.
• Treatment-related side effects were manageable with standard supportive care.
• No Grade 3 or 4 toxicities were observed.
• The randomized Phase 2 trial aims to enroll 100 patients in total.
• Patient accrual is presently ongoing at Cedars-Sinai Medical Center, City of Hope, and Huntsman Cancer Center.

Sentiment

Score: 8

Explanation: The announcement of positive interim safety results for ENV-105 in a Phase 2 trial for mCRPC is a strong positive indicator, showing the drug is well-tolerated with no severe toxicities. This validates its clinical potential and supports continued development in an area of high unmet medical need. However, these are only safety results, and efficacy data is still pending.

Positives

• ENV-105 demonstrated a favorable safety profile in the interim analysis of its Phase 2 trial for mCRPC.
• The drug was well tolerated when combined with apalutamide.
• No dose-limiting toxicities or unexpected adverse events have been reported.
• Treatment-related side effects were manageable with standard supportive care.
• No Grade 3 or 4 toxicities were observed, indicating a strong safety profile.
• The positive safety results validate the belief in ENV-105's clinical potential and support continued development in a patient population with limited effective treatment options.

Risks

• Underlying assumptions in forward-looking statements may prove inaccurate.
• Known or unknown risks or uncertainties could materialize, causing actual results to vary materially from expectations and projections.
• Challenges and uncertainties are inherent in product research and development.
• Uncertainty exists regarding future commercial success.
• Actual events and results may differ materially and are subject to risks, uncertainties, and assumptions described in Kairos Pharma's Annual Report on Form 10-K and other SEC filings.

Future Outlook

Kairos Pharma expects to report interim efficacy data from the Phase 2 trial in September 2025. The company plans to engage with regulatory agencies to discuss the design of a potential pivotal Phase 3 study, based on emerging data.

Management Comments

• "The favorable safety profile observed in this Phase 2 study is encouraging, as it validates our belief in ENV-105s clinical potential and supports continued development in a patient population with limited effective treatment options." John Yu, MD, Kairos Pharma CEO.
• "With one million men in the US being diagnosed with prostate cancer annually, and millions more worldwide, the development of resistance to current hormone therapies is a growing unmet need with an increasingly aging population." John Yu, MD, Kairos Pharma CEO.
• "Kairos Pharma seeks to provide a safe and effective alternative for these patients with ENV-105." John Yu, MD, Kairos Pharma CEO.

Industry Context

The announcement addresses a significant unmet medical need in metastatic castration-resistant prostate cancer (mCRPC), a condition where tumors grow despite hormone blocking agents and treatment options remain limited after hormone therapies fail. With one million men diagnosed with prostate cancer annually in the US, and millions more worldwide, the development of resistance to current hormone therapies is a growing concern, particularly with an increasingly aging population. Kairos Pharma aims to provide a safe and effective alternative for these patients.

Stakeholder Impact

• Shareholders: Positive safety results could increase investor confidence and potentially the stock price, indicating significant progress in the drug pipeline.
• Patients: Offers potential for a new, safe treatment option for metastatic castration-resistant prostate cancer, a condition with limited effective therapies.
• Employees: Positive trial results can boost morale and validate ongoing research and development efforts.
• Regulatory Authorities: The company plans to engage with regulatory agencies to discuss future study designs, indicating ongoing collaboration and adherence to regulatory pathways.

Next Steps

• Continue patient accrual for the randomized Phase 2 trial, aiming to enroll 100 patients in total.
• Report interim efficacy data from the trial in September 2025.
• Engage with regulatory agencies to discuss the design of a potential pivotal Phase 3 study, based on emerging data.

Key Dates

Recommendation

Keywords

Kairos Pharma, ENV-105, carotuximab, prostate cancer, metastatic castration-resistant prostate cancer, mCRPC, CD105 antagonist, clinical trial, Phase 2, biopharmaceutical, oncology, drug development, safety results, apalutamide